Efficacy of astragalus combined with renin-angiotensin-aldosterone system blockers in the treatment of stage III diabetic nephropathy: a systematic review and meta-analysis

References

• Nomura H, Kuruppu S, Rajapakse NW. Stimulation of angiotensin converting enzyme 2: a novel treatment strategy for diabetic nephropathy. Front Physiol. 2021;12:1. doi: 10.3389/fphys.2021.813012.
   Web of Science ®Google Scholar
• Leoncini G, Viazzi F, De Cosmo S, et al. Blood pressure reduction and RAAS inhibition in diabetic kidney disease: therapeutic potentials and limitations. J Nephrol. 2020;33(5):949–13. doi: 10.1007/s40620-020-00803-3.
   PubMed Web of Science ®Google Scholar
• Lam AYR, Zheng HF, Teo KK, et al. Determining diabetic kidney disease severity using traditional Chinese medicine syndrome classification. Singapore Med J. 2021. Epub ahead of print. doi: 10.11622/smedj.2021179.
   Google Scholar
• Wen Y, Yan M, Zhang B, et al. Chinese medicine for diabetic kidney disease in China. Nephrology. 2017;22 Suppl 4(S4):50–55. doi: 10.1111/nep.13149.
   PubMedGoogle Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.
   PubMed Web of Science ®Google Scholar
• Qi C, Mao X, Zhang Z, et al. Classification and differential diagnosis of diabetic nephropathy. J Diabetes Res. 2017;2017:8637138–8637137. doi: 10.1155/2017/8637138.
   PubMed Web of Science ®Google Scholar
• Weeks SM. The cochrane collaboration. West J Nurs Res. 2013;35(10):1249–1250. doi: 10.1177/0193945913491839.
   PubMed Web of Science ®Google Scholar
• Atkins D, Eccles M, Flottorp S, et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches the GRADE working group. BMC Health Serv Res. 2004;4(1):38. doi: 10.1186/1472-6963-4-38.
   PubMed Web of Science ®Google Scholar
• Bs C. Clinical observation of astragalus injection combined with captopril in the treatment of early diabetic nephropathy. J Clin Exp Med. 2009;8(11):2.
   Google Scholar
• Cui B, Wang HT. Clinical observation of lotensin combined with astragalus injection in the treatment of early diabetic nephropathy. Chin J Integr Trad West Nephrol. 2011;12(1):2.
   Google Scholar
• C C. Clinical observation of benazepril combined with astragalus in the treatment of diabetic nephropathy. Mod J Integr Trad Chin West Med. 2010;19(23):2.
   Google Scholar
• Xu CX. Effect of fosinopril combined with astragalus injection on early diabetic nephropathy. Chin J Rural Med. 2012;19(2):2.
   Google Scholar
• Wang FL, et al. Clinical observation of Yiqi Yangyin Xiaozhi Tongluo prescription in treating early diabetic nephropathy. Chin J Integr Trad West Med. 2012;1:4.
   Google Scholar
• Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. doi: 10.1136/bmj.n160.
   PubMed Web of Science ®Google Scholar
• Shi GZ, Lin SS. Effect of astragalus injection on the clinical symptoms and urinary microalbumin in patients with early diabetic nephropathy. Mil Joint Logist. 2015;2(2):4.
   Google Scholar
• Huan HM, et al. Efficacy of losartan potassium combined with Astragalus injection in the treatment of early diabetic nephropathy. Chin J Integr Trad West Nephrol. 2010;11(5):2.
   Google Scholar
• Li H, Xu YC. Effect of Huangqi injection in combined with irbesartan on the vascular endothelial function and CGRP in patients with early DN. J Hainan Med Univ. 2017;23(3):3.
   Google Scholar
• Zeng J,Liu DF, Wang JY. Effect of combining Huangqi injection with enalapril in early DN for treatment of early diabetic nephropathy. J Mod Clin Med. 2010;36(2):2.
   Google Scholar
• Chen JN, Li ZX. Curative effect of irbesartan combined with astragalus injection on 58 patients with early diabetic nephropathy. Chin Community Doctors. 2010;12(22):1.
   Google Scholar
• Chen JP. Effect of Huangqi decoction combined with irbesartan on type 2 diabetic nephropathy. Pract Clin J Integr Trad Chin West Med. 2022;22(15):4.
   Google Scholar
• Fang LY, et al. Clinical study on the effect of Jinqi Yuquan formula in the treatment of diabetic nephropathy of qi and yin deficiency combined with blood stasis type. J Nanjing Univ Trad Chin Med. 2018;34(1):4.
   Google Scholar
• Li M. Combined therapy of Huangqi injection and irbesartan for early period type 2 diabetic nephropathy patients. Medical Forum. 2011;32(9):3.
   Google Scholar
• Pan ML, Xue FM. Bservation of curative effect of Tangshen decoction on early diabetic nephropathy. Beijing J Trad Chin Med. 2009;28(4):2.
   Google Scholar
• Yan QH, et al. Effect of qikui granule on microalbuminuria and progress in patients with early diabetic nephropathy. Chin J Integr Trad West Med. 2018;38(4):5.
   Google Scholar
• Li QJ. Effect of astragalus injection on cellular inflammatory factors in early diabetic nephropathy. Chin J Clin Res. 2012;25(10):2.
   Google Scholar
• Cai R, Cui JH. Effect of astragalus injection on urinary albumin and cytokines in patients with early diabetic nephropathy. Mod J Integr Trad Chin West Med. 2016;25(28):3.
   Google Scholar
• Liu S, et al. Effect of irbesartan combined with astragalus injection on connective tissue growth factor in elderly patients with diabetic nephropathy. Chin J Gerontol. 2015;35(1):3.
   Google Scholar
• Huang SR. Clinical study of shenan decoction in treating early diabetic nephropathy. J Changchun Univ Trad Chin Med. 2011;27(3):2.
   Google Scholar
• Zhang XH, Guo ZJ, Lan CF. Clinical observation of Bushen Jianpi, Yiqi Tongluo prescription combined with valsartan in the treatment of diabetic nephropathy proteinuria. Chin J Integr Trad West Nephrol. 2018;19(2):4.
   Google Scholar
• Lu XL, Chen XM. Effect of Shenqi Qinerxian decoction on diabetic nephropathy (stage III) and its influence on renal function. Glob Trad Chin Med. 2017;10(11):3.
   Google Scholar
• Liu XX, Xiao M, Liu B. Effect of astragalus injection on urinary albumin and cytokines in patients with early diabetic nephropathy. Chin J Exp Trad Med Formulae. 2013;19(9):5.
   Google Scholar
• Liu XX, Meng X, Wei N. Effect of astragalus membranaceus on endothelin and calcitonin gene-related peptide in early diabetic nephropathy patients. Chin J Gerontol. 2015;000(008):3.
   Google Scholar
• Yc C, et al. Clinical trial of qishen tongluo granules in the treatment of diabetic nephropathy in stage III. Chin J Clin Pharmacol. 2018;34(07):3.
   Google Scholar
• Sun YH, Zhao FL, Ding XY. Clinical observation of telmisartan combined with astragalus injection in the treatment of early diabetic nephropathy. Chin J Integr Trad West Nephrol. 2014;15:2.
   Google Scholar
• Zhang Y. Effect of astragalus injection combined with valsartan in treating diabetic nephropathy. Med Pharm J Chin Peoples Liberation Army. 2012;024(008):3.
   Google Scholar
• Ren YJ. Effect of Huangqi injection in combined with irbesartan on the microcirculation and CTGF in patients with early DN. J Hainan Med Univ. 2016;22(22):4.
   Google Scholar
• Lu Y. Q., clinical effect of huangqi granule combined with lotensin on early diabetic nephropathy. Chin J Exp Trad Med Formulae. 2009;15(7):3.
   PubMedGoogle Scholar
• Liu ZK, Xie R. Observation on the curative effect of irbesartan, astragalus injection and insulin in treating early diabetic nephropathy. Clin Med Eng.. 2012;19(6):2.
   Google Scholar
• Xu ZX. Clinical observation of 28 patients with early diabetic nephropathy treated with valsartan combined with Astragalus injection. GUANGXI Med J. 2009;31(6):3.
   Google Scholar
• Sonmez A. Challenges in the prevention and management of diabetic kidney diseases. Front Clin Diabetes Healthc. 2021;2:728320. doi: 10.3389/fcdhc.2021.728320.
   PubMedGoogle Scholar
• Ai X, et al. A review of traditional Chinese medicine on treatment of diabetic retinopathy and involved mechanisms. Biomed Pharmacother. 2020;132:110852.
   PubMed Web of Science ®Google Scholar
• Zhou H, Ni W-J, Meng X-M, et al. Corrigendum: microRNAs as regulators of immune and inflammatory responses: potential therapeutic targets in diabetic nephropathy. Front Cell Dev Biol. 2022;10:875280. doi: 10.3389/fcell.2022.875280.
   PubMed Web of Science ®Google Scholar
• Tan B, et al. The effect of ibrutinib on radiosensitivity in pancreatic cancer cells by targeting EGFR/AKT/mTOR signaling pathway. Biomed Pharmacother. 2020;128:110133.
   PubMed Web of Science ®Google Scholar
• Guo M, et al. Astragalus polysaccharide ameliorates renal inflammatory responses in a diabetic nephropathy by suppressing the TLR4/NF-kappaB pathway. Drug Des Devel Ther. 2023;17:2107–2118.
   PubMed Web of Science ®Google Scholar
• Ren G, et al. Baicalin exerts a protective effect in diabetic nephropathy by repressing inflammation and oxidative stress through the SphK1/S1P/NF-kappaB signaling pathway. Diabetes Metab Syndr Obes. 2023;16:1193–1205.
   PubMed Web of Science ®Google Scholar
• Vodošek Hojs N, Bevc S, Ekart R, et al. Oxidative stress markers in chronic kidney disease with emphasis on diabetic nephropathy. Antioxidants. 2020;9(10):925. doi: 10.3390/antiox9100925.
   Web of Science ®Google Scholar
• Lin Y, et al. Astragaloside IV ameliorates streptozotocin induced pancreatic beta-Cell apoptosis and dysfunction through SIRT1/P53 and akt/GSK3beta/Nrf2 signaling pathways. Diabetes Metab Syndr Obes. 2022;15:131–140.
   PubMed Web of Science ®Google Scholar
• Chen JY, et al. Based on the network pharmacology, and molecular docking to explore the mechanism of action of diabetes, renal Ann soup treatment of diabetic nephropathy. Chin J Gerontol. 2022;42(23):7.
   Google Scholar
• Li ZQ. Curative effect of astragalus injection combined with telmisartan in the treatment of early diabetic nephropathy. Clin Med Res. 2010;27(3):3.
   Google Scholar
• Zhang GY, Liu YS, Sui HY. Clinical observation of Yiqi Ziyin Tongluo prescription combined with Western medicine in the treatment of early diabetic nephropathy. Chin J Trad Med Sci Technol. 2018;25(4):3.
   Google Scholar
• Tu X, Liu F, Jordan JB, et al. Huang Qi Elixir’ for proteinuria in patients with diabetic nephropathy: a study protocol for a randomized controlled pilot trial. Trials. 2013;14(1):223. doi: 10.1186/1745-6215-14-223.
   PubMedGoogle Scholar
• Krisanapan P, Sanpawithayakul K, Pattharanitima P, et al. Safety and efficacy of GLP-1 receptor agonists in type 2 diabetes mellitus with advanced and end-stage kidney disease: a systematic review and meta-analysis. Diseases. 2024;12(1):14. doi: 10.3390/diseases12010014.
   PubMedGoogle Scholar
• Kanduri SR, et al. SGLT2 inhibitors and kidney outcomes in patients with chronic kidney disease. J Clin Med. 2020;9(9):2723.
   PubMed Web of Science ®Google Scholar